文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

乳腺癌中的巨噬细胞生物学和免疫抑制机制。

Macrophage Biology and Mechanisms of Immune Suppression in Breast Cancer.

机构信息

Breast Tumor Immunology Laboratory, Dana-Farber Cancer Institute, Boston, MA, United States.

Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, United States.

出版信息

Front Immunol. 2021 Apr 23;12:643771. doi: 10.3389/fimmu.2021.643771. eCollection 2021.


DOI:10.3389/fimmu.2021.643771
PMID:33968034
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8102870/
Abstract

Macrophages are crucial innate immune cells that maintain tissue homeostasis and defend against pathogens; however, their infiltration into tumors has been associated with adverse outcomes. Tumor-associated macrophages (TAMs) represent a significant component of the inflammatory infiltrate in breast tumors, and extensive infiltration of TAMs has been linked to poor prognosis in breast cancer. Here, we detail how TAMs impede a productive tumor immunity cycle by limiting antigen presentation and reducing activation of cytotoxic T lymphocytes (CTLs) while simultaneously supporting tumor cell survival, angiogenesis, and metastasis. There is an urgent need to overcome TAM-mediated immune suppression for durable anti-tumor immunity in breast cancer. To date, failure to fully characterize TAM biology and classify multiple subsets has hindered advancement in therapeutic targeting. In this regard, the complexity of TAMs has recently taken center stage owing to their subset diversity and tightly regulated molecular and metabolic phenotypes. In this review, we reveal major gaps in our knowledge of the functional and phenotypic characterization of TAM subsets associated with breast cancer, before and after treatment. Future work to characterize TAM subsets, location, and crosstalk with neighboring cells will be critical to counteract TAM pro-tumor functions and to identify novel TAM-modulating strategies and combinations that are likely to enhance current therapies and overcome chemo- and immuno-therapy resistance.

摘要

巨噬细胞是维持组织内稳态和抵御病原体的重要先天免疫细胞;然而,它们浸润肿瘤与不良预后相关。肿瘤相关巨噬细胞(TAMs)是乳腺癌炎症浸润的重要组成部分,TAMs 的广泛浸润与乳腺癌预后不良相关。在这里,我们详细介绍了 TAMs 如何通过限制抗原呈递和减少细胞毒性 T 淋巴细胞(CTL)的激活,同时支持肿瘤细胞存活、血管生成和转移,来阻碍有效的肿瘤免疫循环。为了在乳腺癌中获得持久的抗肿瘤免疫,迫切需要克服 TAM 介导的免疫抑制。迄今为止,由于未能充分表征 TAM 生物学并对多个亚群进行分类,因此在治疗靶向方面进展缓慢。在这方面,由于 TAMs 亚群多样性和严格调控的分子和代谢表型,其复杂性最近成为关注焦点。在这篇综述中,我们揭示了与乳腺癌治疗前后 TAM 亚群功能和表型特征相关的主要知识空白。未来对 TAM 亚群的特征、位置以及与邻近细胞的相互作用进行研究,对于抵抗 TAM 促进肿瘤的功能以及鉴定新的 TAM 调节策略和组合以增强现有治疗方法并克服化疗和免疫治疗耐药性将是至关重要的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3eed/8102870/2ef49547f91b/fimmu-12-643771-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3eed/8102870/54c01b4aa92a/fimmu-12-643771-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3eed/8102870/66ada16d3a99/fimmu-12-643771-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3eed/8102870/827c1d013bfb/fimmu-12-643771-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3eed/8102870/2ef49547f91b/fimmu-12-643771-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3eed/8102870/54c01b4aa92a/fimmu-12-643771-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3eed/8102870/66ada16d3a99/fimmu-12-643771-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3eed/8102870/827c1d013bfb/fimmu-12-643771-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3eed/8102870/2ef49547f91b/fimmu-12-643771-g0004.jpg

相似文献

[1]
Macrophage Biology and Mechanisms of Immune Suppression in Breast Cancer.

Front Immunol. 2021

[2]
Macrophage Polarization: Anti-Cancer Strategies to Target Tumor-Associated Macrophage in Breast Cancer.

J Cell Biochem. 2017-9

[3]
The role of tumor-associated macrophage in breast cancer biology.

Histol Histopathol. 2018-2

[4]
Heat shock protein 27 differentiates tolerogenic macrophages that may support human breast cancer progression.

Cancer Res. 2011-1-11

[5]
Single-cell transcriptional atlas of tumor-associated macrophages in breast cancer.

Breast Cancer Res. 2024-9-4

[6]
Tumor Associated Macrophages as Therapeutic Targets for Breast Cancer.

Adv Exp Med Biol. 2017

[7]
TFEB is a master regulator of tumor-associated macrophages in breast cancer.

J Immunother Cancer. 2020-6

[8]
The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies.

Neuro Oncol. 2017-10-19

[9]
CCL18 from tumor-associated macrophages promotes angiogenesis in breast cancer.

Oncotarget. 2015-10-27

[10]
The roles of tumor-associated macrophages in tumor angiogenesis and metastasis.

Cell Immunol. 2020-7

引用本文的文献

[1]
Dual roles of innate immune cells and cytokines in shaping the breast cancer microenvironment.

Front Immunol. 2025-8-20

[2]
Identification and validation of cell phagocytosis-related genes for prognosis in breast cancer: A study of diagnostic relevance in breast cancer.

Medicine (Baltimore). 2025-8-1

[3]
Comprehensive analysis of glycosyl transferase-related subtypes reveals prognostic genes and immune landscape in breast cancer.

Medicine (Baltimore). 2025-8-1

[4]
Integrated network toxicology and bioinformatics reveal PFAS-driven prognostic biomarkers and molecular mechanisms in breast cancer: insights from transcriptome analysis and molecular docking.

Discov Oncol. 2025-7-24

[5]
Tumor-Associated Macrophage in Breast Tumor Microenvironment.

Int J Mol Sci. 2025-6-21

[6]
Spatial profiling reveals unique immune microenvironment in premenopausal triple-negative breast cancer associated with therapy response.

J Transl Med. 2025-7-10

[7]
Developmental immune network of airway lymphocytes and innate immune cells in patients with stable COPD.

Front Immunol. 2025-6-16

[8]
Progress of Traditional Chinese Medicine in Regulating Immune Cell in the Tumor Microenvironment of Triple-Negative Breast Cancer.

Integr Cancer Ther. 2025

[9]
New Insights Into Adipokines and the Tumor Microenvironment in Breast Cancer.

Cancer Control. 2025

[10]
CD105 fibroblasts support an immunosuppressive niche in women at high risk of breast cancer initiation.

Breast Cancer Res. 2025-5-15

本文引用的文献

[1]
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer.

Nat Cancer. 2021-1

[2]
Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer.

Clin Cancer Res. 2021-2-15

[3]
Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of -Mutant Breast Cancer.

Cancer Res. 2021-2-1

[4]
Local Targeting of Lung-Tumor-Associated Macrophages with Pulmonary Delivery of a CSF-1R Inhibitor for the Treatment of Breast Cancer Lung Metastases.

Mol Pharm. 2020-12-7

[5]
Immunological Differences Between Immune-Rich Estrogen Receptor-Positive and Immune-Rich Triple-Negative Breast Cancers.

JCO Precis Oncol. 2020-6-26

[6]
Pathologic assessment of tumor-associated macrophages and their histologic localization in invasive breast carcinoma.

J Egypt Natl Canc Inst. 2020-1-27

[7]
Tumor-Associated Macrophages: Recent Insights and Therapies.

Front Oncol. 2020-2-25

[8]
Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis.

Front Immunol. 2020

[9]
Evaluating the Polarization of Tumor-Associated Macrophages Into M1 and M2 Phenotypes in Human Cancer Tissue: Technicalities and Challenges in Routine Clinical Practice.

Front Oncol. 2020-1-24

[10]
Macrophage Colony-stimulating Factor Mediates the Recruitment of Macrophages in Triple negative Breast Cancer.

Int J Biol Sci. 2019-11-8

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索